Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a ...

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

PM CDT at the ASCO Annual MeetingMIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ...

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge. A recent review published in Genes & Diseases offers a comprehensive ...

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on ...

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer-related deaths worldwide. The mutational landscape of CRC is well ...

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer ...